BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma and Renal Impairment
Authors:
- Alma HabibAHAlma Habib
- Nausheen AhmedNANausheen Ahmed
- Abdullah Mohammad KhanAbdullah Mohammad Khan
- Darryl ChangDCDarryl Chang
- Barry PaulBPBarry Paul
- Hira ShaikhHSHira Shaikh
- Christopher StrouseCSChristopher Strouse
- Emily StrubleESEmily Struble
- Andrew VegelAVAndrew Vegel
- Zahra MahmoudjafariZMZahra Mahmoudjafari
- Muhammad Umair MushtaqMMMuhammad Umair Mushtaq
- Joseph P. McGuirkJMJoseph P. McGuirk
Top Cited Papers
Open Access
- 30 January 2026
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 33 (2) , 80
Abstract
The pivotal clinical trials, CARTITUDE-1 and KarMMa-3, showed promising response rates in relapsed and refractory multiple myeloma (RRMM) with use of BCMA-directed CAR T-cell therapy; however, a major challenge is determining suitability in patients who do not meet trial inclusion criteria due to suboptimal organ function. In this multicenter retrospective study, we evaluated the safety and efficacy of BCMA CAR-T therapy in patients with RRMM and renal impairment (RI), defined as creatinine clearance (CrCL) of less than 45 mL/min. We evaluated 223 patients treated with idecabtagene vicleucel (ide-cel) or ciltacabtagene autoleucel (cilta-cel) between May 2021 and April 2024. Outcomes were compared between baseline RI (11.2%) and normal renal function (nRF) cohorts. Response rates were similar at 1 month (p = 0.09), 3 months (p > 0.9), and 6 months (p = 0.8). Progression-free survival (PFS) was 21.9 months in the RI group compared to 15 months in the nRF group (p = 0.32), while overall survival (OS) was 27.9 months for patients with nRF versus not reached for patients with RI (p = 0.87). Patients with RI had higher rates of immune effector cell-associated neurotoxicity syndrome (ICANS) (60% vs. 19%, p = 0.04) and infections (44% vs. 20%, p = 0.008). We found that BCMA CAR-T demonstrated comparable efficacy in RRMM patients with baseline RI, although these patients exhibited increased rates of neurotoxicity and infections.Keywords
This publication has 21 references indexed in Scilit:
- Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast NephropathyAmerican Journal of Hematology, 2025
- Acute kidney injury in hematological patients treated with CAR-T cells: risk factors, clinical presentation and impact on outcomesScientific Reports, 2024
- Infectious Complications in Patients with Hematologic Malignancies Receiving CD19 Vs. BCMA Targeted CAR-T TherapyTransplantation and Cellular Therapy, 2024
- The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCLAmerican Journal of Hematology, 2023
- Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell TherapyTransplantation and Cellular Therapy, 2023
- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaNew England Journal of Medicine, 2023
- Post-CAR-T Cell Therapy (Consolidation and Relapse): Multiple Myeloma2022
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyThe Lancet, 2021
- A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemiaClinical and Translational Medicine, 2021
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaNew England Journal of Medicine, 2021